供应商 · 生产商 · 工业生物技术与生物基材料

Tsingke Biotechnology

擎科生物（Tsingke Biotech）是合成生物学领域的领导者，致力建设世界级基因工厂：把 AI 驱动的分子制造与基因读取、编辑和合成的专长相整合，建立了覆盖从原料到测序完整生物技术流程的完全自主研发生态。在这一生态内，公司开发三大智能制造平台：高通量寡核苷酸筛选、抗体发现与生产、微生物菌株工程与筛选。平台以自产试剂、专有合成仪和自动化系统为动力，为基因设计、合成和功能分子发现提供可扩展、精准的方案，赋能生物制药、工业生物技术、农业、食品和环境科学的应用。公司总部位于北京，运营 70,000 平方米设施，持有 300 多项专利，质量、环境与职业健康管理体系均获认证；生产环境通过 ISO 13485 认证，并持有二类和三类医疗器械许可……

运营中中国亚洲成立 2017 营收: RMB 6.33亿元 (year not specified in extracted text; described as revenue increasing over the ‘last three years’ with values 5.00亿元, 5.66亿元, and 6.33亿元). 核实于 2026-10-05

简介

Beijing Tsingke Biotech Co., Ltd. is a China-based biotechnology company that provides integrated DNA and RNA synthesis services, molecular reagents, and synthetic biology tools for research and industrial applications. Its core platform, the Gene Factory, utilizes proprietary automated synthesizers, in-house reagents, and AI-driven workflows to support services including oligonucleotide synthesis, gene synthesis (up to 200 kb), protein and antibody expression, and GMP-compliant nucleic acid production for therapeutics.

Founded in 2002 and incorporated in 2017, the company is headquartered in Beijing E-Town, China. It is a venture-backed firm that converted to a joint-stock company in 2023 and successfully listed on the National Equities Exchange and Quotations (NEEQ) in January 2026. As of 2026, the company remains active, employing over 1,200 people and serving more than 300,000 customers globally. Recent developments include the launch of a redesigned global website, strategic partnerships with firms like iGeneTech, and the expansion of its small nucleic acid therapeutic capabilities.

Sources#

行业: 食品配料, 工业化学
主题: 基因合成、测序与生物工具, 合成生物学平台与生物制造, 酵母、发酵与食品配料
角色: 生产商 — “…Its core platform, the Gene Factory, utilizes proprietary automated synthesizers, in-house reagents, and AI-dr…”

供应的生物解决方案 0

尚未被列为已评级方案的供应商。

产品与服务

该公司未公开其产品或服务——我们可通过引荐了解。

新闻与状态 6

2026 最新状态: 公司于2026年在全国中小企业股份转让系统（NEEQ，新三板）挂牌。 ↗ ↗ ↗
2026-04-15 Tsingke Unveils 'Zero-Contact' Gene Synthesis to Safeguard Core Genetic Sequences
Tsingke Biotech is promoting a security-first approach to gene synthesis with its new “Zero-Contact Sequences” system, an on-site, fully automated platform designed to minimize exposure of core genetic sequences and protect intellectual property. The company …
2026-09-22 Tsingke Enables High-Throughput Validation of AI-Designed Proteins and Antibodies
Tsingke Biotechnology has launched an integrated high-throughput workflow to experimentally validate large libraries of AI-designed proteins and antibodies, combining gene synthesis, parallel expression, screening, and quantitative binding analysis to …
2026-01-20 Tsingke Biotech Launches New Website to Streamline Global Biotech R&D and Translational Services
Tsingke Biotech announces the launch of a redesigned global website featuring a "Gene Factory" model to streamline end-to-end DNA/RNA manufacturing and biotech R&D services, highlighting integrated capabilities across molecular biology, gene therapy, …
2026-06-30 Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics – HK Businesswire
Tsingke Biotech positions itself as a leading innovator in small nucleic acid therapeutics, offering an integrated platform for siRNA/ASO development, GMP-grade production, and AI-assisted optimization, while emphasizing collaboration across academia, …
2026-07-08 Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026 - Thailand Business News
Tsingke showcased AI-assisted discovery of highly selective CLDN18.2 antibodies at AIS 2026, highlighting an AI-enabled workflow to reduce cross-reactivity and its end-to-end antibody development platform (discovery, engineering, and protein expression).
2026-03-10 Tsingke Biotech and iGeneTech Forge Strategic Partnership to Lead Synthetic Biology Advancements - Beijing Tsingke Biotech Co., Ltd.
Tsingke Biotech is expanding its capabilities through a strategic partnership with iGeneTech to advance synthetic biology. The collaboration signals a focus on leadership in the synthetic biology field and ongoing growth through alliances.

关系网络：股东、合作伙伴、同类

股权与投资方 1

母公司

Ma Shijin

合作与交易 1

合作	GeneTech …ustomers globally. Recent developments include the launch of a redesigned global website, strategic partnerships with firms like iGeneTech, and the expansion of its small nucleic acid therapeutic ……

身份与联系方式

联系方式、人员和法律信息仅向会员开放。

会员登录